W. Scott Willett
Corporate Officer/Principal bei Promedior, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Richard Jack | M | - |
Promedior, Inc.
 Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 10 Jahre |
| Nancy Thomason | F | - |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | - |
| John H. Friedman | M | 71 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | - |
| Augustine Lawlor | M | 67 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | - |
| Howard Weisman | M | 64 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 11 Jahre |
| Geert-Jan Mulder | M | 58 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | - |
| Richard Bucala | M | - |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Suzanne Bruhn | M | 60 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 3 Jahre |
| Dominick Colangelo | M | 60 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 4 Jahre |
| Jason Lettmann | M | 46 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 6 Jahre |
| Mark Lupher | M | 53 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 6 Jahre |
| Russell Ellison | M | 76 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | - |
| Daniel Geffken | M | 67 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 8 Jahre |
| Amir Nashat | M | 51 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 10 Jahre |
| William Hodder | M | - |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 1 Jahre |
| Elizabeth G. Trehu | M | 64 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 3 Jahre |
| Hanns A. Pielenz | M | - |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 17 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- W. Scott Willett
- Persönliches Netzwerk
